Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Daniela Graham"'
Autor:
Joseph Fowler, Jeffrey Sugarman, Lawrence Sher, Chuanbo Zang, John L. Werth, Daniela E. Myers, Daniela Graham, Alexander Agyei Marfo, Liza Takiya
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 4, Pp 951-960 (2023)
Plain Language Summary Atopic dermatitis (AD), also known as eczema, is a chronic skin disease that causes red or flaky skin patches that can become infected and itch. Children with AD often experience sleep disturbance, including difficulty falling
Externí odkaz:
https://doaj.org/article/9f3154ed08464b0a9bf4d464568f6ef9
Autor:
Daniela Graham, Philip S Helliwell, Christopher Ritchlin, Alexis Ogdie, Jon T Giles, Rebecca Germino, Lori Stockert, Pamela Young, Wael Joseph, Rajiv Mundayat, Juan J Gómez-Reino
Publikováno v:
RMD Open, Vol 7, Iss 1 (2021)
Objectives This post-hoc analysis explored the impact of body mass index (BMI) on tofacitinib efficacy/safety in patients with active psoriatic arthritis (PsA).Methods Data were pooled from two phase 3 studies (NCT01877668; NCT01882439). Analyses inc
Externí odkaz:
https://doaj.org/article/8fdeb69b5f6f4eb9b2ab37d9bcf0083f
Autor:
Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu
Publikováno v:
RMD Open, Vol 5, Iss 1 (2019)
Objectives Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to ≥1 conventional synthetic disease-modifying antirheumatic drug (cs
Externí odkaz:
https://doaj.org/article/3ce70b78fcd64432b61b5c5d39a99ba1
Autor:
Filip Van den Bosch, James Cheng-Chung Wei, Peter Nash, Francisco J. Blanco, Daniela Graham, Chuanbo Zang, Edmund Arthur, Cecilia Borlenghi, Vassilis Tsekouras, Bonnie Vlahos, Atul Deodhar
Publikováno v:
JOURNAL OF RHEUMATOLOGY
ObjectiveRE-EMBARK investigated etanercept (ETN) withdrawal and retreatment in patients with nonradiographic axial spondyloarthritis (nr-axSpA) achieving inactive disease.MethodsPatients received ETN and a background nonsteroidal antiinflammatory dru
Publikováno v:
The Journal of Dermatology. 48:1640-1651
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, xerosis, and eczematous lesions. In Japan, treatment options, such as topical corticosteroids and tacrolimus, are associated with efficacy and safety concerns. C
Autor:
Manfred Hauben, Keith S. Kanik, Joel M. Kremer, Jeffrey R. Curtis, Christina Charles-Schoeman, Alina Onofrei, Eric Hung, Stanley Cohen, Cunshan Wang, Hernan Valdez, Thomas V. Jones, Carol A. Connell, Philip J. Mease, Ann Madsen, Jeff Greenberg, Wendi Malley, Daniela Graham, Lara Fallon, John Woolcott, Huifeng Yun
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO). Routine pharmacovigilance of an ongoing, open-label, bli
Autor:
Kim Papp, Joseph Wu, Peter Nash, Wolf-Henning Boehncke, Joseph F. Merola, M-A Hsu, Jordi Gratacós, Daniela Graham, Cunshan Wang, P. Young, Diamant Thaçi
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 12 (2020) pp. 2809-2820
Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 12 (2020) pp. 2809-2820
Background Psoriatic arthritis (PsA) is a chronic, systemic immune‐mediated inflammatory musculoskeletal disease. The onset of dermatologic symptoms often precedes rheumatic manifestations. Tofacitinib is an oral Janus kinase inhibitor for the trea
Autor:
Manoli Vourvahis, Wonkyung Byon, Cheng Chang, Vu Le, Annette Diehl, Daniela Graham, Sakambari Tripathy, Nancy Raha, Lina Luo, Sumathy Mathialagan, Martin Dowty, A. David Rodrigues, Bimal Malhotra
Publikováno v:
Clinical pharmacology and therapeutics. 112(3)
Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor currently approved in the United Kingdom for the treatment of moderate-to-severe atopic dermatitis (AD). As patients with AD may use medications to manage comorbidities, abrocitinib could be used
Autor:
Daniela Graham, Dafna D. Gladman, Arthur Kavanaugh, Désirée van der Heijde, Lara Fallon, Cunshan Wang, Oliver FitzGerald
Publikováno v:
Journal of Rheumatology, 46(9), 1089-1096
Objective.To evaluate the effect of baseline risk factors on radiographic progression in patients with active psoriatic arthritis (PsA) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and were
Autor:
Julie S. Shepard, John C Su, Charles Lynde, Bonnie Vlahos, Chuanbo Zang, Richard G. Gower, Joel Schlessinger, John L. Werth, Liza Takiya, Daniela Graham, Amy Cha
Publikováno v:
Section on Advances in Therapeutics and Technology Program.